Thrombotic microangiopathy complicating newly diagnosed Sjögren's syndrome in a dialysis patient

1Citations
Citations of this article
16Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Thrombotic microangiopathy (TMA) is rarely associated with Sjögren's syndrome (SS). This is the first documented case of a patient undergoing chronic hemodialysis with SS who developed TMA. TMA is an infrequent, life-threatening multisystem disorder characterized by microangiopathic hemolytic anemia and thrombocytopenia, accompanied by microvascular thrombosis that causes variable degrees of tissue ischemia and infarction. It is important to make a quick diagnosis of TMA to cure the reported case as early as possible. The patients with TMA should be diagnosed quickly, and in this case plasma exchange and corticosteroids in combination with cyclophosphamide have been associated with a recurrence free period. Cyclophosphamide has led to the development of treatment protocols using alternative immunosuppressive agents in patients with SS showing a poor response to plasmapheresis and potentially life-threatening manifestations. Further research is required to ascertain the sensitivity, specificity, efficacy, timing, cost-benefit ratio, and necessity of cyclophosphamide in the setting of TMA complicating SS. © 2014 Informa Healthcare USA, Inc. All rights reserved: reproduction in whole or part not permitted.

Cite

CITATION STYLE

APA

Cheng, M. H., Lin, J. H., Yen, T. H., Wang, H. T., Chen, M. C., Huang, H. L., … Wang, W. J. (2014). Thrombotic microangiopathy complicating newly diagnosed Sjögren’s syndrome in a dialysis patient. Renal Failure, 36(7), 1162–1165. https://doi.org/10.3109/0886022X.2014.917764

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free